2.0
13. Juli 2012
Ehemaliger Mitarbeiter, mehr als 1 Jahr
Ramat Gan
Empfehlen
CEO-Befürwortung
Geschäftsprognose
Pros
The product itself is simple in concept, and could make a big difference in the preemptive detection of one of the most aggressive cancer types there are (i.e., colon cancer).
Kontras
There is some obscurity as to how a machine that has gone through FDA approval 2009 and got its CE is not yet in the market. I took part in its successes in human trials 2008-2009, which where very promising (success rate of exams was reported as better than the reference STD colonoscopy, performed).